Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 31Recurrence 6Sarcoma, Kaposi 2Neoplasms 2Acquired Immunodeficiency Syndrome 2Plasmacytoma 1Plasmablastic Lymphoma 1Neoplasms, Plasma Cell 1Multi-centric Castleman's Disease 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Epstein-Barr Virus Infections 1Burkitt Lymphoma 1

Interventions

Rituximab 2pomalidomide 1dehydroftorafur 1Watchful Waiting 1Vincristine 1Taxes 1Radiotherapy, Intensity-Modulated 1Prednisone 1Platinum 1Paclitaxel 1Nivolumab 1Gemcitabine 1Fluorouracil 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epstein-Barr Virus Infections × pomalidomide × 30 days × Clear all
NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡